EUVIMEDEUVIMED entdecken
Crossref

Reply to: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial

Michael Wang, Jutta K. Neuenburg, Constantine S. Tam

AME Clinical Trials Review · 2026-04 · 4 · 21-21

DOI: 10.21037/actr-26-0007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-04. Verfasst von Michael Wang und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Wang, M., Neuenburg, J. K., & Tam, C. S. (2026). Reply to: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial. AME Clinical Trials Review, 4, 21-21. https://doi.org/10.21037/actr-26-0007

Vancouver

Wang M, Neuenburg JK, Tam CS. Reply to: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial. AME Clinical Trials Review. 2026;4:21-21. doi:10.21037/actr-26-0007

BibTeX
@article{Wang2026,
  author = {Wang, Michael and Neuenburg, Jutta K. and Tam, Constantine S.},
  title = {Reply to: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial},
  journal = {AME Clinical Trials Review},
  year = {2026},
  volume = {4},
  pages = {21--21},
  doi = {10.21037/actr-26-0007}
}
Kostenlos starten →